Drugs / Pagoclone
Pagoclone
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT00370981 | Jul 2006 | premature ejaculation | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 2 | NCT00216255 | Apr 2005 → Jul 2011 | stutter disorder | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 2 | NCT00239915 | Apr 2005 → Dec 2006 | stutter disorder | Pharmacology Research Institute | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00830154 | Feb 2009 → Jan 2010 | stutter disorder | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pagoclone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00216255 ↗ |
| Known as | CI-1043 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104745 ↗ |
| Known as | IP 456 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104745 ↗ |
| Known as | Pagoclona | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104745 ↗ |
| Known as | RP 62955 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104745 ↗ |
| Modality | Small molecule | — CHEMBL2104745 ↗ |